Hepatocellular cancer and liver transplantation: necessity to go from chaos to order

Cover Page

Cite item

Abstract

The care for liver-diseased patients presenting with hepatocellular cancer (HCC) is changing rapidly. Many treatment possibilities and caregivers belonging to a multitude of specialities troubled the therapeutic algorithm of the liver cancer patients. HCC in both normal and diseased livers has to be considered firstly as a surgical disease. The possibilities of surgery, including liver resections, as well as liver transplantation, have been underestimated and even been minimalized mainly as a consequence of many studies promoting in an unlimited way all different kinds of locoregional non-surgical and systemic therapies. Locoregional therapies and surgical procedures should not be seen as competing, but as complementary treatment options. Locoregional therapies are of value if surgery is not possible; in the context of transplantation they have an important role as ‘downstaging procedures’ allowing for bringing of transplantable patients into the required inclusion criteria. Systemic therapies and living donor liver transplantation will without any doubt occupy a more important role in the future therapeutic scheme of HCC.

About the authors

J. Lerut

University Hospitals Saint Luc, Université Catholique de Louvain

Author for correspondence.
Email: jan.lerut@uclouvain.be

Jan Lerut – MD, PhD, Professor.

10, Hippocrates avenue, 1200 Brussels, tel.: + 32 475 85 95 04, Fax: + 32 2 764 90 39

Belgium

S. Iesari

University of L’Aquila

Email: fake@neicon.ru

Samuele Iesari – MD, Department of Biotechnological and Applied Clinical Sciences.

25 Via Giovanni Falcone, Coppito (AQ), 67100

Italy

M. Foguenne

University Hospitals Saint Luc, Université Catholique de Louvain

Email: fake@neicon.ru

Maxime Foguenne – MD, Starzl Unit Abdominal Transplantation.

10 Hippocrates avenue, Brussels, 1200

Belgium

K. Ackenin

University Hospitals Saint Luc, Université Catholique de Louvain

Email: fake@neicon.ru

Kevin Ackenin – MD, Starzl Unit Abdominal Transplantation.

10 Hippocrates avenue, Brussels, 1200

Belgium

Q. Lai

La Sapienza University

Email: fake@neicon.ru

Quirino Lai – MD, PhD, Department of General Surgery and Organ Transplantation.

5 Piazzale Aldo Moro, Roma, 00185

Italy

References

  1. Starzl TE, Demetris AJ. Liver transplantation: a 31-year perspective. In: Current Problems in Surgery. Vol. 27. Chicago: Year Book Medical Publishers; 1990.
  2. Starzl TE. Experience in hepatic transplantation. Philadelphia: W.B. Saunders Co; 1969. 553 p.
  3. Pichlmayr R, Weimann A, Oldhafer KJ, Schlitt HJ, Tusch G, Raab R. Appraisal of transplantation for malignant tumours of the liver with special reference to early stage hepatocellular carcinoma. Eur J Surg Oncol. 1998;24(1): 60–7. doi: 10.1016/S07487983(98)80130-3.
  4. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993;218(2): 145–51.
  5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11): 693–9. doi: 10.1056/NEJM199603143341104.
  6. Lai Q, Lerut JP. Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Curr Opin Organ Transplant. 2014;19(3): 229–34. doi: 10.1097/MOT.0000000000000085.
  7. Hwang S, Moon DB, Lee SG. Liver transplantation and conventional surgery for advanced hepatocellular carcinoma. Transpl Int. 2010;23(7): 723–7. doi: 10.1111/j.14322277.2010.01103.x.
  8. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6): 1394–403. doi: 10.1053/jhep.2001.24563.
  9. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1): 35–43. doi: 10.1016/S1470-2045(08)70284-5.
  10. Lencioni R, Crocetti L, De Simone P, Filipponi F. Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects. Transpl Int. 2010;23(7): 698–703. doi: 10.1111/j.14322277.2010.01109.x.
  11. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi E, Makuuchi M. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg. 2013;257(5): 929–37. doi: 10.1097/SLA.0b013e31828329b8.
  12. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M. Report of the 17th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37(9): 676–91. doi: 10.1111/j.1872034X.2007.00119.x.
  13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1): 182–236. doi: 10.1016/j.jhep.2018.03.019.
  14. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4): 378–90. doi: 10.1056/NEJMoa0708857.
  15. Longo V, Gnoni A, Casadei Gardini A, Pisconti S, Licchetta A, Scartozzi M, Memeo R, Palmieri VO, Aprile G, Santini D, Nardulli P, Silvestris N, Brunetti O. Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget. 2017;8(20): 33897–910. doi: 10.18632/oncotarget.15406.
  16. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13(1):e11–22. doi: 10.1016/S14702045(11)70175-9.
  17. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Kubo S, Sakamoto M, Nakashima O, Kumada T, Kokudo N; Liver Cancer Study Group of Japan. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. Hepatology. 2017;66(2): 510–7. doi: 10.1002/hep.29225.
  18. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7): 1691–700.e3. doi: 10.1053/j.gastro.2014.02.032.
  19. Takamoto T, Sugawara Y, Hashimoto T, Makuuchi M. Evaluating the current surgical strategies for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2016;10(3): 341–57. doi: 10.1586/17474124.2016.1116381.
  20. Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralcyk A, Hörbelt R, Kroemer A, Loss M, Rümmele P, Scherer MN, Padberg W, Königsrainer A, Lang H, Obed A, Schlitt HJ. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255(3): 405–14. doi: 10.1097/SLA.0b013e31824856f5.
  21. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127): 1301–14. doi: 10.1016/S0140-6736(18)30010-2.
  22. Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016;64(6): 2077–88. doi: 10.1002/hep.28643.
  23. Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, Goffette P, Vogel W, Pitton MB, Lerut J; European Hepatocellular Cancer Liver Transplant Study Group. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl. 2013;19(10): 1108–18. doi: 10.1002/lt.23706.
  24. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux GP, Chazouillères O, Salame E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D; Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143(4): 986–94.e3. doi: 10.1053/j.gastro.2012.05.052.
  25. Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology. 2015;62(1): 158–65. doi: 10.1002/hep.27787.
  26. Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K, Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007;13(12): 1637–44. doi: 10.1002/lt.21281.
  27. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85(12): 1726–32. doi: 10.1097/TP.0b013e31816b67e4.
  28. Todo S, Furukawa H, Tada M; Japanese Liver Transplantation Study Group. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2007;13(11 Suppl 2):S48–54. doi: 10.1002/lt.21334.
  29. Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, Yu SJ, Lee JW, Yi NJ, Lee KW, Kim SH, Kim JM, Joh JW, Teperman LW, Park JS, Kim YJ, Suh KS, Yoon JH. Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg. 2016;263(5): 842–50. doi: 10.1097/SLA.0000000000001578.
  30. Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int. 2014;27(1): 32–41. doi: 10.1111/tri.12191.
  31. Lesurtel M, Müllhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant. 2006;6(11): 2644–50. doi: 10.1111/j.16006143.2006.01509.x.
  32. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1): 52–60. doi: 10.1055/s-0030-1247132.
  33. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D, Adam R. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10(1): 129–37. doi: 10.1111/j.1600-6143.2009.02750.x.
  34. Manzia TM, Lai Q, Iesari S, Perera MTPR, Komuta M, Carvalheiro A, Shah T, Angelico R, Quaranta C, Nicolini D, Montalti R, Scarpelli M, Palmieri G, Orlacchio A, Vivarelli M, Angelico M, Lerut J, Tisone G. Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients, a multicentre cohort study. Transpl Int. 2018;31(9): 988–98. doi: 10.1111/tri.13153.
  35. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55(4): 814–9. doi: 10.1016/j.jhep.2010.12.040.
  36. Hong G, Suh KS, Suh SW, Yoo T, Kim H, Park MS, Choi Y, Paeng JC, Yi NJ, Lee KW. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol. 2016;64(4): 852–9. doi: 10.1016/j.jhep.2015.11.033.
  37. Lerut J, Iesari S, Foguenne M, Lai Q. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? Transl Gastroenterol Hepatol. 2017;2:80. doi: 10.21037/tgh.2017.09.06.
  38. Lerut JP, Pinheiro RS, Lai Q, Stouffs V, Orlando G, Juri JM, Ciccarelli O, Sempoux C, Roggen FM, De Reyck C, Latinne D, Gianello P. Is minimal, [almost] steroid-free immunosuppression a safe approach in adult liver transplantation? Long-term outcome of a prospective, double blind, placebo-controlled, randomized, investigator-driven study. Ann Surg. 2014;260(5): 886–91. doi: 10.1097/SLA.0000000000000969.
  39. Lee SG. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. Am J Transplant. 2015;15(1): 17–38. doi: 10.1111/ajt.12907.
  40. Friemel J, Rechsteiner M, Frick L, Böhm F, Struckmann K, Egger M, Moch H, Heikenwalder M, Weber A. Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res. 2015;21(8): 1951–61. doi: 10.1158/1078-0432.CCR-14-0122.
  41. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310(22): 1427–31. doi: 10.1056/NEJM198405313102204.
  42. Nakao A, Virji A, Iwaki Y, Carr B, Iwatsuki S, Starzl E. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma. Hepatogastroenterology. 1991;38(5): 450–3.
  43. Lai Q, Nicolini D, Inostroza Nunez M, Iesari S, Goffette P, Agostini A, Giovagnoni A, Vivarelli M, Lerut J. A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation: Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) Score. Ann Surg. 2016;264(5): 787–96. doi: 10.1097/SLA.0000000000001881.
  44. Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F, Cillo U; Italian Liver Cancer group. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol. 2011;12(7): 654–62. doi: 10.1016/S1470-2045(11)70144-9.
  45. Cillo U, Burra P, Mazzaferro V, Belli L, Pinna AD, Spada M, Nanni Costa A, Toniutto P; I-BELT (Italian Board of Experts in the Field of Liver Transplantation). A multistep, consensus-based approach to organ allocation in liver transplantation: toward a "blended principle model". Am J Transplant. 2015;15(10): 2552–61. doi: 10.1111/ajt.13408.
  46. Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Spoletini G, Hoppe-Lotichius M, Vennarecci G, Manzia TM, Nicolini D, Avolio AW, Frigo AC, Graziadei I, Rossi M, Tsochatzis E, Otto G, Ettorre GM, Tisone G, Vivarelli M, Agnes S, Cillo U, Lerut J; European Hepatocellular Cancer Liver Transplant Study Group. Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology. 2017;66(6): 1910–9. doi: 10.1002/hep.29342.
  47. Yang JD, Kim WR, Park KW, Chaiteerakij R, Kim B, Sanderson SO, Larson JJ, Pedersen RA, Therneau TM, Gores GJ, Roberts LR, Park JW. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology. 2012;56(2): 614–21. doi: 10.1002/hep.25680.
  48. Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, De Carlis L, Belli L, Colledan M, Fagiuoli S, Rossi G, Andorno E, Baccarani U, Regalia E, Vivarelli M, Donataccio M, Cillo U; Liver Transplantation North Italy Transplant program (NITp) working group. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol. 2014;60(2): 290–7. doi: 10.1016/j.jhep.2013.10.010.
  49. Berry K, Ioannou GN. Comparison of liver transplant-related survival benefit in patients with versus without hepatocellular carcinoma in the United States. Gastroenterology. 2015;149(3): 669–80. doi: 10.1053/j.gastro.2015.05.025.

Copyright (c) 2018 Lerut J., Iesari S., Foguenne M., Ackenin K., Lai Q.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies